BeOne Medicines (NASDAQ:ONC) Stock Gets Price Target Increase from JPMorgan Chase & Co.

BeOne Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan raised BeOne Medicines’ price target to $460 from $445 and maintained an “overweight” rating, implying 14.7% upside from the prior close.
  • Analyst sentiment is broadly positive: MarketBeat reports an average “Buy” rating and an average price target of $441.64, with 17 analysts rating the stock Buy or Strong Buy and one rating it Hold.
  • BeOne reported quarterly EPS of $3.64, beating the $2.34 consensus, while revenue of $1.89 billion also exceeded expectations of $1.76 billion.
  • MarketBeat previews top five stocks to own in December.

BeOne Medicines (NASDAQ:ONC - Get Free Report) had its price objective increased by JPMorgan Chase & Co. from $445.00 to $460.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target would indicate a potential upside of 14.70% from the stock's previous close.

ONC has been the subject of several other research reports. Barclays raised their price target on BeOne Medicines from $415.00 to $446.00 and gave the company an "overweight" rating in a report on Friday, November 6th. Nomura upped their price objective on shares of BeOne Medicines from $454.75 to $484.91 and gave the company a "buy" rating in a report on Thursday, August 6th. Citizens Jmp upped their price objective on shares of BeOne Medicines from $405.00 to $463.00 and gave the company a "market outperform" rating in a report on Friday, November 6th. Wolfe Research reissued an "outperform" rating and issued a $370.00 price objective on shares of BeOne Medicines in a research report on Monday, August 10th. Finally, Wells Fargo & Company raised their target price on shares of BeOne Medicines from $400.00 to $435.00 and gave the stock an "overweight" rating in a research note on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $441.64.

View Our Latest Stock Report on ONC

BeOne Medicines Stock Performance

NASDAQ ONC traded down $2.56 during trading on Thursday, reaching $401.05. 122,481 shares of the company's stock were exchanged, compared to its average volume of 321,343. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.55 and a quick ratio of 3.19. The business has a 50 day moving average price of $372.52 and a 200-day moving average price of $329.28. The stock has a market capitalization of $44.03 billion, a P/E ratio of 51.04 and a beta of 0.63. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $424.73.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.34 by $1.30. BeOne Medicines had a return on equity of 19.04% and a net margin of 13.86%. The company had revenue of $1.89 billion during the quarter, compared to analysts' expectations of $1.76 billion. Sell-side analysts forecast that BeOne Medicines will post 9.98 earnings per share for the current fiscal year.

Insider Buying and Selling at BeOne Medicines

In related news, insider Titus B. Ball sold 1,559 shares of the company's stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $405.57, for a total value of $632,283.63. Following the transaction, the insider directly owned 880 shares in the company, valued at approximately $356,901.60. This represents a 63.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Xiaobin Wu sold 280 shares of the firm's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total transaction of $106,400.00. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 135,571 shares of company stock valued at $48,487,792. 6.19% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP lifted its position in shares of BeOne Medicines by 101.3% during the 3rd quarter. Allworth Financial LP now owns 153 shares of the company's stock valued at $56,000 after acquiring an additional 77 shares during the period. Baker BROS. Advisors LP grew its holdings in shares of BeOne Medicines by 0.3% during the 3rd quarter. Baker BROS. Advisors LP now owns 8,832,335 shares of the company's stock worth $3,232,105,000 after purchasing an additional 30,768 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of BeOne Medicines by 28.0% in the third quarter. Goldman Sachs Group Inc. now owns 201,873 shares of the company's stock worth $73,873,000 after purchasing an additional 44,172 shares during the period. Bellevue Group AG increased its position in shares of BeOne Medicines by 31.6% in the third quarter. Bellevue Group AG now owns 13,785 shares of the company's stock worth $5,044,000 after purchasing an additional 3,311 shares during the period. Finally, Integral Health Asset Management LLC acquired a new position in BeOne Medicines in the third quarter valued at about $18,297,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.

See Also

Analyst Recommendations for BeOne Medicines (NASDAQ:ONC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BeOne Medicines Right Now?

Before you consider BeOne Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.

While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines